Myeloma Paper of the Day, August 2nd, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: A nomogram incorporating age, beta 2 microglobulin, and deletion 17p status may accurately and consistently predict the prognosis of primary plasma cell leukemia (PCL) patients.”
Source: Robert Orlowski/X
Authors: Jingjing Deng, Xiaoqi Qin, Guangyu Ma, Xuliang Shen, Jingnan Sun, Yanhong Zhao, Zhihua Zhang, Ying Sun, Guitao Jie, Liping Su, Jie Ma, Weiwei Tian, Lin Yang, Qingming Wang, Hongming Huang, Mingxia Shi, Yanping Ma, Wen Gao and Wenming Chen.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
